PPARγ regulates resistance vessel tone through a mechanism involving rgs5-mediated control of protein kinase c and BKCa channel activity

Circulation Research

Volumn 111, Issue 11, 2012, Pages 1446-1458

  Ketsawatsomkron, Pimonrat ^a   Lorca, Ramón A ^a   Keen, Henry L ^a   Weatherford, Eric T ^a   Liu, Xuebo ^a   Pelham, Christopher J ^a   Grobe, Justin L ^a   Faraci, Frank M ^a   England, Sarah K ^a   Sigmund, Curt D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

hypertension; myogenic tone; peroxisome proliferator activated receptor ; protein kinase C; regulator of G protein signaling 5

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN II; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE C; RGS PROTEIN; RGS5 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTERY RESISTANCE; ARTERY TONE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; MALE; MESENTERIC ARTERY; MICROCIRCULATION; MOUSE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION PROFILING; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNITS; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; MUTATION; MYOCYTES, SMOOTH MUSCLE; NAPHTHALENES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; PPAR GAMMA; PROTEIN KINASE C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RGS PROTEINS; RNA INTERFERENCE; TETRAETHYLAMMONIUM; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84870039725     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.271577     Document Type: Article

References (36)

1. Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta. 2007;1771:926-935.
2. Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem. 2010;285:9311-9316.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocar-dial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
4. Govindan J, Evans M. Pioglitazone in clinical practice: where are we now? Diabetes Ther. 2012;3:1-8.
5. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
6. Tsai YS, Kim HJ, Takahashi N, Kim HS, Hagaman JR, Kim JK, Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J Clin Invest. 2004;114:240-249.
7. Gray SL, Nora ED, Grosse J, Manieri M, Stoeger T, Medina-Gomez G, Burling K, Wattler S, Russ A, Yeo GS, Chatterjee VK, O'Rahilly S, Voshol PJ, Cinti S, Vidal-Puig A. Leptin defciency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes. 2006;55:2669-2677.
8. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008;7:215-226.
9. Hill MA, Meininger GA, Davis MJ, Laher I. Therapeutic potential of pharmacologically targeting arteriolar myogenic tone. Trends Pharmacol Sci. 2009;30:363-374.
10. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
11. Jackson-Weaver O, Paredes DA, Gonzalez Bosc LV, Walker BR, Kanagy NL. Intermittent hypoxia in rats increases myogenic tone through loss of hydrogen sulfde activation of large-conductance Ca(2+)-activated potassium channels. Circ Res. 2011;108:1439-1447.
12. Paternò R, Heistad DD, Faraci FM. Functional activity of Ca2+-dependent K+ channels is increased in basilar artery during chronic hypertension. Am J Physiol. 1997;272:H1287-H1291.
13. Zhou XB, Wulfsen I, Utku E, Sausbier U, Sausbier M, Wieland T, Ruth P, Korth M. Dual role of protein kinase C on BK channel regulation. Proc Natl Acad Sci USA. 2010;107:8005-8010.
14. Laher I, Zhang JH. Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab. 2001;21:887-906.
15. Loufrani L, Lehoux S, Tedgui A, Lévy BI, Henrion D. Stretch induces mitogen-activated protein kinase activation and myogenic tone through 2 distinct pathways. Arterioscler Thromb Vasc Biol. 1999;19:2878-2883.
16. Baek EB, Jin C, Park SJ, Park KS, Yoo HY, Jeon JH, Earm YE, Kim SJ. Differential recruitment of mechanisms for myogenic responses according to luminal pressure and arterial types. Pfugers Arch. 2010;460:19-29.
17. Schubert R, Lidington D, Bolz SS. The emerging role of Ca2+ sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc Res. 2008;77:8-18.
18. Manzur M, Ganss R. Regulator of G protein signaling 5: a new player in vascular remodeling. Trends Cardiovasc Med. 2009;19:26-30.
19. Wang Q, Liu M, Mullah B, Siderovski DP, Neubig RR. Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Biol Chem. 2002;277:24949-24958.
20. Keen HL, Halabi CM, Beyer AM, de Lange WJ, Liu X, Maeda N, Faraci FM, Casavant TL, Sigmund CD. Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome pro-liferator-activated receptor gamma in mouse aorta. Arterioscler Thromb Vasc Biol. 2010;30:518-525.
21. Zarzuelo MJ, Jimenez R, Galindo P, et al. Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats. Hypertension. 2011;58:733-743.
22. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK. PPARdelta-mediated antiinfammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA. 2008;105:4277-4282.
23. Li G, Leff T. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes. Mol Endocrinol. 2007;21:857-864.
24. Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Børgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG. Genome-wide profling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 2008;22:2953-2967.
25. Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, Tuteja G, Manduchi E, Grant GR, Lazar MA. Cell-specifc determinants of peroxi-some proliferator-activated receptor gamma function in adipocytes and macrophages. Mol Cell Biol. 2010;30:2078-2089.
26. Adhikary T, Kaddatz K, Finkernagel F, Schonbauer A, Meissner W, Scharfe M, Jarek M, Blocker H, Muller-Brusselbach S, Muller R. Genomewide analyses defne different modes of transcriptional regulation by peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). PLoS One. 2011;6:e16344.
27. Chen TT, Luykenaar KD, Walsh EJ, Walsh MP, Cole WC. Key role of Kv1 channels in vasoregulation. Circ Res. 2006;99:53-60.
28. Bonev AD, Jaggar JH, Rubart M, Nelson MT. Activators of protein ki-nase C decrease Ca2+ spark frequency in smooth muscle cells from cerebral arteries. Am J Physiol. 1997;273:C2090-C2095.
29. Mederos y Schnitzler M, Storch U, Meibers S, Nurwakagari P, Breit A, Essin K, Gollasch M, Gudermann T. Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction. EMBO J. 2008;27:3092-3103.
30. Chang YP, Liu X, Kim JD, Ikeda MA, Layton MR, Weder AB, Cooper RS, Kardia SL, Rao DC, Hunt SC, Luke A, Boerwinkle E, Chakravarti A. Multiple genes for essential-hypertension susceptibility on chromosome 1q. Am J Hum Genet. 2007;80:253-264.
31. Adams LD, Geary RL, McManus B, Schwartz SM. A comparison of aorta and vena cava medial message expression by cDNA array analysis identifes a set of 68 consistently differentially expressed genes, all in aortic media. Circ Res. 2000;87:623-631.
32. Helledie T, Grøntved L, Jensen SS, Kiilerich P, Rietveld L, Albrektsen T, Boysen MS, Nøhr J, Larsen LK, Fleckner J, Stunnenberg HG, Kristiansen K, Mandrup S. The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. J Biol Chem. 2002;277:26821-26830.
33. Semple RK, Meirhaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, Gibbons GF, Gurnell M, Chatterjee VK, O'Rahilly S. A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology. 2005;146:1871-1882.
34. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Blüher M, Griffn PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466:451-456.
35. Griffn SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991;17:626-635.
36. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res. 2007;101:441-454.